You are on page 1of 4

Global Vaccine Market to reach USD 60 Billion, by the end of year 2022

Global Vaccine Market to reach USD 60 Billion, by the end
of year 2022

Analyst View:
Global Vaccines Market to reach US$ 60 Billion by the year 2022. Pediatric vaccines market is
having a dominant market share compared to Adult vaccines market. By 2022 Pediatric
vaccines market share will be double the size of adult vaccines market share.

For More Information:
http://www.renub.com/global-vaccine-market-to-reach-usd-60-billion-by-the-end-of-year-
2022-49-nd.php

Access Full Research: http://www.renub.com/global-vaccines-market-and-forecast-
14-vaccines-market-number-of-people-immunized-doses-of-vaccines-administered-
1200-p.php

Get 10% Free Customization in this Report

Global vaccine market is probable to reach US$ 60 Billion by the end of year 2022 says the
recent report published by Renub Research entitled “Global Vaccines Market & Forecast” by 14
vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis,
Dtap, Travel and Miscellaneous, Haemophilus Influenzae Type b (Hib), Combos, Polio,
Rotavirus, Varicella), number of immunized person, number of vaccines doses administered and
company sales – forecast to 2022.

Vaccines Prevent Diseases
With so many diseases in the world, there needs to be something to protect people from getting
sick and even dying. So, we have vaccines to protect ourselves from getting sick. In simple
words, Vaccines immunize and protect people from several serious diseases such as measles,
meningitis, pneumonia, Influenza, rubella and polio.

© Renub Research LLP Page 1 of 4
Global Vaccine Market to reach USD 60 Billion, by the end of year 2022

Era of Vaccines
A number of vaccines have been developed (e.g. cervical cancer and dengue vaccine) and
several others are already on its way to hit the market at earliest (e.g. malaria and zika
vaccines), making last 15 years the most productive in the history of vaccines development.

Industrialized countries already have a robust system of immunization programmes while
developing countries are trying their best to implement such programmes to save a million
lives.
Request a free sample copy of the report: http://www.renub.com/contactus.php

Vaccine Market Briefing
Pneumococcal vaccine is the largest segment for vaccine and it terms of value it accounts more
than US$ 7 Billion in 2016. The Pneumococcal vaccine sale is primarily driven by increasing
utilization of Pneumococcal vaccines products worldwide, and especially in the US, where the
Advisory Committee on Immunization Practices (ACIP) strictly recommends its inoculation.
While there is also a considerable boost in the market size of Cervical Cancer Vaccine as many
countries around the world efficiently focused on the causalities caused by this disease, thus
recommend all women must get Cervical Cancer Vaccine to prevent cervical cancer.

Table of Contents
1. Research Findings

2. Global – Vaccines Market and Forecast

3. Global – Adult Vaccine vs. Pediatric Vaccine Market Share

4. Global – Vaccines Market Share and Forecast

5. Global – People Immunized and Forecast

6. Global – People Immunized Share and Forecast

7. Global – Doses of Vaccines Administered and Forecast

8. Global – Doses of Vaccines Administered Share and Forecast

9. Global – Vaccine Companies Market Share and Forecast

10. Disease wise – Vaccines Market and Forecast
10.1 Influenza – Total Vaccines Market and Forecast
10.2 Cervical Cancer (HPV) – Vaccines Market and Forecast
10.3 Zoster (Shingles) – Vaccines Market and Forecast

© Renub Research LLP Page 2 of 4
Global Vaccine Market to reach USD 60 Billion, by the end of year 2022

10.4 MMRV and MMR (Measles, Mumps, Rubella, and Varicella Vaccine) – Total Vaccines Market and
Forecast
10.5 Pneumococcal – Total Vaccines Market and Forecast
10.6 Meningococcal – Total Vaccines Market and Forecast
10.7 Hepatitis – Total Vaccines Market and Forecast
10.8 TdaP and DTaP – Total Vaccines Market and Forecast
10.9 Travel and Miscellaneous – Vaccines Market and Forecast
10.10 Haemophilus Influenzae Type B (HIB) – Vaccines Market and Forecast
10.11 Combos (Combination) – Vaccines Market and Forecast
10.12 Polio – Vaccines Market and Forecast
10.13 Rotavirus – Vaccines Market and Forecast
10.14 Varicella – Vaccines Market and Forecast

11. Disease wise – People Immunized Numbers and Forecast
11.1 Influenza – Total Number of People Immunized and Forecast
11.2 Cervical Cancer (HPV) – People Immunized and Forecast
11.3 Zoster (Shingles) – Number of People Immunized and Forecast
11.4 MMRV and MMR – Total Number of People Immunized and Forecast
11.5 Pneumococcal – Total Number of People Immunized and Forecast
11.6 Meningococcal – Total Number of People Immunized and Forecast
11.7 Hepatitis – Total Number of People Immunized and Forecast
11.8 TdaP and DTaP – Total Number of People Immunized and Forecast
11.9 Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized and Forecast
11.10 Combos (Combination Vaccines) – Number of Infants Immunized and Forecast
11.11 Polio – Number of Infants Immunized and Forecast
11.12 Rotavirus – Number of Infants Immunized and Forecast
11.13 Varicella – Number of Infants Immunized and Forecast

12. Disease wise – Doses of Vaccines Administered and Forecast
12.1 Influenza – Doses of Vaccines Administered and Forecast
12.2 Cervical Cancer (HPV) – Doses of Vaccines Administered and Forecast
12.3 Zoster (Shingles) – Doses of Vaccines Administered and Forecast
12.4 MMRV and MMR – Doses of Vaccines Administered and Forecast
12.5 Pneumococcal – Doses of Vaccines Administered and Forecast
12.6 Meningococcal – Doses of Vaccines Administered and Forecast
12.7 Hepatitis – Doses of Vaccines Administered and Forecast
12.8 TdaP and DTaP – Doses of Vaccines Administered and Forecast
12.9 Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast
12.10 Polio – Doses of Infant Vaccines Administered and Forecast
12.11 Rotavirus – Doses of Infant Vaccines Administered and Forecast
12.12 Varicella – Doses of Infant Vaccines Administered and Forecast

13. Disease wise - Immunization Profile
13.1 Immunization Coverage (%) in Infants (2005 – 2015)
13.2 Global Immunization Profile (2011 – 2015)
13.3 Regional Immunization Profile (2001 – 2015)
14. Vaccines Key Players Sales and Forecast
14.1 GlaxoSmithKline, plc.’s Vaccines Sales and Forecast
14.2 Merck & Co. Vaccines Sales and Forecast
14.3 Sanofi Pasteur’s Vaccines Sales and Forecast
14.4 Worldwide - Pfizer, Inc.’s Vaccines Sales and Forecast
14.5 Worldwide - Others Vaccines Sales and Forecast

15. Vaccines – Products and Pipeline
15.1 GSK Vaccine Product Pipeline

© Renub Research LLP Page 3 of 4
Global Vaccine Market to reach USD 60 Billion, by the end of year 2022

15.2 Merck Vaccine Product Pipeline
15.3 Sanofi Vaccine Product Pipeline
15.4 Pfizer Vaccine Product Pipeline

16. Top Mergers and Acquisitions in the Vaccine Industry

17. Vaccines and Regulator’s Interventions

18. Vaccine Market Drivers
18.1 Inclusion in National Immunization Schedule
18.2 Growing Immunization Coverage for HPV Vaccines
18.3 Increase in Prevalence of Infectious Diseases
18.4 Global Immunization Vision and Strategy (GIVS)
18.5 GAVI Model Fuelling Vaccine Manufacturers
18.6 Increasing Vaccine Availability in United States
18.7 The Vaccine Safety Data link Project
18.8 The Vaccine Injury Compensation Program
18.9 Transforming of Vaccine Technologies
18.10 Global Vaccine Action Plan by WHO (2011 - 2020)
18.11 Continuous Focus on Effective Communication Strategies

19. Vaccines Market Challenges
19.1 Hurdles to Optimal use of Licensed Vaccines
19.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
19.3 Shortening the Timeline for Vaccine Development
19.4 Refusal/Resistance to Vaccination
19.5 Vaccine Shortages and Delays
19.6 Obstacles in Vaccine Research & Development
19.7 Barriers to New Entrants in the Vaccines Market

Vaccines Market Report:
http://www.renub.com/vaccines-12-c.php

Renub Research - North America Renub Research - Asia
Rajat Gupta Ankit Mishra
225 Kristie Ln, Roswell C – 86, Sector – 10
Georgia 30076, United States Noida 201301, India

Tel: +1-678-302-0700 Tel: +91-120-421-9822
Email: info@renub.com Email: info@renub.com
www.renub.com www.renub.com

© Renub Research LLP Page 4 of 4